Full Breakdown
The 2025 U.S. Generic & Biosimilar Medicines Savings Report: An Overview of Savings and Challenges
9/5/2025, 11:00:12 AM
Significant Savings from Generics and Biosimilars
The 2025 U.S. Generic & Biosimilar Medicines Savings Report, released by the Association for Accessible Medicines (AAM) and the Biosimilars Council, highlights that generic and biosimilar medicines generated $467 billion in savings for patients and the U.S. healthcare system in 2024. Over the past decade, these alternatives have saved more than $3.4 trillion. Despite making up 90% of all prescriptions filled in the U.S., generics and biosimilars account for only 12% of total drug spending, with brand-name drugs comprising the remaining 10% but consuming 88% of the expenditure.
The Current Landscape of Biosimilars
Biosimilars, which are biologic products highly similar to already approved reference biologics, have contributed $56.2 billion in savings since their introduction in 2015. They have been utilized in approximately 3.3 billion days of patient therapy, significantly expanding patient access. However, the report indicates a concerning trend: only 12 out of 118 biologics expected to lose patent exclusivity in the next decade currently have biosimilars in development, creating what is termed a "biosimilar void." This gap threatens to limit future savings opportunities, estimated at $234 billion.
Challenges Facing the Generic and Biosimilar Market
John Murphy III, President and CEO of AAM, emphasized the need for policy reform to ensure the sustainability of the generic and biosimilar markets. He noted that the significant price deflation over the past 30 years could lead to unsustainable conditions for manufacturers, potentially jeopardizing patient care and increasing the risk of drug shortages. Key recommendations include streamlining FDA processes, curbing patent abuse, and addressing the role of pharmacy benefit managers (PBMs) and Medicare policies that may restrict patient access.
Criticism of Market Dynamics
Critics argue that both drug manufacturers and PBMs contribute to barriers in the biosimilar market. Issues such as patent thickets, which involve overlapping intellectual property rights that delay market entry for biosimilars, have been highlighted. Additionally, PBMs have been accused of favoring higher-cost products over cheaper biosimilars, which can lead to increased out-of-pocket costs for patients. For instance, CVS Caremark's launch of private-label biosimilars while excluding lower-cost options exemplifies the complexities of pricing and access in the U.S. market.
Official Statements and Responses
Giuseppe Randazzo, Interim Executive Director of the Biosimilars Council, noted the progress made in the biosimilars industry but stressed the urgent need for action to address the current development void. He stated, “Sustainability of our industry is not guaranteed—we must double down efforts to ensure the biosimilars market reaches its full potential.”
Verbatim Quotes
- “Simply put: Generic medicines save money,” — John Murphy III, President and CEO of AAM
- “However, over the next decade, 118 biologics are expected to lose patent exclusivity, presenting a $234 billion opportunity for biosimilars.” — Giuseppe Randazzo, Interim Executive Director, Biosimilars Council
Conclusion
The 2025 U.S. Generic & Biosimilar Medicines Savings Report underscores the critical role of generics and biosimilars in reducing healthcare costs while highlighting significant challenges that could hinder future savings. Addressing these barriers is essential for ensuring continued access to affordable medications for American patients.
